



ASSESSING THE EFFICACY OF ANTHELMINTHIC DRUGS AGAINST SCHISTOSOMIASIS AND SOIL-TRANSMITTED HELMINTHIASES



World Health
Organization



ASSESSING THE EFFICACY OF ANTHELMINTHIC DRUGS AGAINST SCHISTOSOMIASIS AND SOIL-TRANSMITTED HELMINTHIASES



WHO Library Cataloguing-in-Publication Data

Assessing the efficacy of anthelmintic drugs against schistosomiasis and soil-transmitted helminthiases.

1.Schistosomiasis – drug therapy. 2.Helminthiasis – drug therapy. 3.Anthelmintics – therapeutic use. 4.Soil – parasitology. 5.Neglected diseases. I.World Health Organization.

ISBN 978 92 4 156455 7

(NLM classification: QV 253)

© World Health Organization 2013

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in France.

WHO/HTM/NTD/PCT/2013.4



CONTENTS

ACKNOWLEDGEMENTS	v
1. BACKGROUND AND OBJECTIVES	1
2. WHEN TO ASSESS THE EFFICACY OF ANTHELMINTHIC DRUGS	3
3. ASSESSMENT OF THE EFFICACY OF ANTHELMINTHIC DRUGS	4
3.1 School selection and communication with school personnel and families	4
3.2 Sample size and selection of children	4
3.3 Baseline survey	6
3.4 Drug administration	7
3.5 Parasitological examination	7
3.6 Follow-up survey	8
4. STATISTICAL ANALYSIS	10
4.1 Calculation of egg reduction rate	10
4.2 Evaluation of the results	10
5. INSTITUTIONS TO BE CONTACTED IN CASE OF REDUCED DRUG EFFICACY	11
6. REFERENCES	12
ANNEXES	14
Annex 1. Possible confounding factors in the assessment of anthelmintic drug efficacy	14
Annex 2. Recommended dose and reference efficacy (egg reduction rate) for selected anthelmintic drugs	17
Annex 3. Example of information letter for schools	21
Annex 4. Example of informed consent form	22
Annex 5. Useful addresses	23
Annex 6. Form for collecting personal data and information on parasites	24
Annex 7. Standard operating procedures for laboratory methods	25



ACKNOWLEDGEMENTS

The World Health Organization (WHO) expresses special thanks to all those who contributed to the preparation of this manual. The writing committee comprised: Antonio Montresor, WHO, Geneva, Switzerland; Bruno Levecke, Ghent University, Merelbeke, Belgium; Marco Albonico, Ivo de Carneri Foundation, Milan, Italy; Piero Olliaro, WHO, Geneva, Switzerland; and Jozef Vercruysse, Ghent University, Merelbeke, Belgium.

Thanks are also extended to the following people for their contributions, suggestions and support: David Addis, Children Without Worms, Atlanta, Georgia, USA; Lester Chitsulo, WHO, Geneva, Switzerland; Jean Tenena Coulibaly, Swiss Tropical and Public Health Institute, Basel, Switzerland; Nilanthi De Silva, University of Kelaniya, Kelaniya, Sri Lanka; Dirk Engels, WHO, Geneva, Switzerland; Albis Gabrielli, WHO, Geneva, Switzerland; Jiagang Guo, WHO, Geneva, Switzerland; Theresa Gyorkos, McGill University, Montreal, Canada; Stefanie Knopp, Swiss Tropical and Public Health Institute, Basel, Switzerland; Simone Magnino, WHO, Geneva, Switzerland; Pamela Mbabazi, WHO, Geneva, Switzerland; Maria Rebollo, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; Valerio Reggi, WHO, Geneva, Switzerland; Mussa Sacko, Institut National de Recherche en Santé Publique, Bamako, Mali; Russell Stothard, Liverpool University, Liverpool, United Kingdom; Juerg Utzinger, Swiss Tropical and Public Health Institute, Basel, Switzerland; and Aya Yajima, WHO, Geneva, Switzerland.



预览已结束，完整报告链接和二

<https://www.yunbaogao.cn/report/index/report?repo>

